Sanofi’s Amlitelimab Shows Promise but Falls Short of Dupixent in Atopic Dermatitis

Sanofi released Phase III results for amlitelimab, its potential successor to Dupixent, in atopic dermatitis (AD). In the COAST 2 trial, amlitelimab met a co-primary endpoint in the US but narrowly missed EU targets, showing modest improvements in vIGA-AD 0/1 scores and EASI-75 reductions. The SHORE trial demonstrated stronger results, particularly when combined with topical corticosteroids: EU patients achieved vIGA-AD 0/1 at rates of 29.9–32.9%, and EASI-75 outcomes reached 48.1–50.9%, compared with 16.8–34.2% for placebo.

Across trials, amlitelimab was safe and well-tolerated, with common adverse events including nasopharyngitis and upper respiratory infections. Analysts note that while the drug does not outperform Dupixent, its differentiated dosing, safety profile, and potential long-term immune 

25-01-2026